GENE ONLINE|News &
Opinion
Blog

2022-01-07| Asia-Pacific

GeneOnline’s Top 10 Hong Kong Biotech IPOs of 2021

by GeneOnline
Share To
Hong Kong is Asia’s largest and the world’s second-largest destination for biotech companies wanting to go public. Amidst the backdrop of COVID-19 and changes in the political and regulatory environment in 2021, companies have forged on to make a splash on the HKEX. Here are 10 of them, ranked by the size of their IPOs. 

GO Prime with only $1.49 now

LATEST
NDA for Biogen-Sage’s Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development
2023-02-07
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
2023-02-07
FDA Expands Approval For Takeda’s Takhzyro To Prevent Hereditary Angioedema Attacks
2023-02-06
Abbott’s New Technologies for Arrhythmia Treatment Secure FDA and European Approval
2023-02-04
First Human Trial for Marburg Virus Vaccine Reports Success
2023-02-03
Karuna Licenses Goldfinch’s Mood Disorder Candidates For Potential $535 Million
2023-02-03
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
2023-02-03
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!